(Q44245024)

1 December 2017

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities (English)

1 reference

1 December 2017

1 reference

1 reference

1 reference

Marisa M Mussi-Pinhata

5

1 reference

1 December 2017

4

Regis Kreitchmann

1 reference

1 December 2017

Mario Ferreira Peixoto

1

1 reference

1 December 2017

José Henrique Pilotto

2

1 reference

1 December 2017

Sonia Karolina Stoszek

3

1 reference

1 December 2017

Victor Hugo Melo

6

1 reference

1 December 2017

Esaú Custodio João

7

1 reference

1 December 2017

Mariana Ceriotto

8

1 reference

1 December 2017

Ricardo da Silva de Souza

9

1 reference

1 December 2017

Jennifer Read

10

1 reference

1 December 2017

1 May 2011

1 reference

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

1 December 2017

1 reference

1 December 2017

15

1 reference

1 December 2017

3

1 reference

1 December 2017

253-261

1 reference

Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Reduced lopinavir exposure during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Lopinavir protein binding in HIV-1-infected pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Pharmacokinetic changes during pregnancy and their clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Concentrations of protease inhibitors in cord blood after in utero exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Management of human immunodeficiency virus-infected pregnant women at Latin American and Caribbean sites

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2811%2970185-4

7 January 2021

10.1016/S1413-8670(11)70185-4

Identifiers

DOI

1 reference

1 December 2017

1 reference